Online inquiry

IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4476MR)

This product GTTS-WQ4476MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD28 gene. The antibody can be applied in Lupus nephritis, Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001243077.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 940
UniProt ID P10747
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4476MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5919MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ15085MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ14411MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ963MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ15784MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ3706MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ6902MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ11677MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW